With tens and possibly hundreds of billions of dollars in potential savings still snagged in a regulatory limbo, federal lawmakers and health industry stakeholders strongly urged the Food and Drug Administration last month to knock down the final barriers to review and approval of biosimilar drugs for marketing in the United States.
U.S. Sens. Dick Durbin, D-Ill., and Richard Blumenthal, D-Conn., on Thursday introduced legislation that would retool the labeling requirements for dietary supplement manufacturers, require pre-market certification on new products and require successful efficacy trials.
Three Democratic lawmakers on Wednesday released a report that found inconsistencies in the labeling and classification of energy drinks, extensive marketing to adolescents and young adults through social media and events, and high caffeine levels that exceed what is considered safe in soda by the Food and Drug Administration.
Top-level executives from more than a dozen major U.S. companies on Monday joined with government officials to launch a nationwide public-private sector initiative to advance employment of people with disabilities.
George Paz, Express Scripts chairman and CEO, and David Snow, Medco Health Solutions chairman and CEO, were in a pair of hot seats Tuesday afternoon before the Senate Committee on the Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights.
The dietary supplement industry last week took another legislative knock to the chin as it was associated with controversy surrounding mislabled conventional foods, specifically Lazy Cakes, a brownie that contains the dietary ingredient melatonin and purports to be a dietary supplement.